Revive Therapeutics Ltd. (RVV.CN)
- Previous Close
0.0250 - Open
0.0300 - Bid 0.0200 x --
- Ask 0.0300 x --
- Day's Range
0.0250 - 0.0300 - 52 Week Range
0.0050 - 0.0350 - Volume
114,664 - Avg. Volume
239,247 - Market Cap (intraday)
10.464M - Beta (5Y Monthly) 1.64
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date May 28, 2025 - Jun 2, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders. It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks. The company also develops Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases. Revive Therapeutics Ltd. is based in Toronto, Canada.
revivethera.com--
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: RVV.CN
View MorePerformance Overview: RVV.CN
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RVV.CN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RVV.CN
View MoreValuation Measures
Market Cap
10.46M
Enterprise Value
9.72M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.64
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-16.18%
Return on Equity (ttm)
-66.49%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-5.29M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
55.41k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.47M